Voyager Therapeutics, Inc. - Common Stock (VYGR)

1.7300
+0.0300 (1.76%)
NASDAQ · Last Trade: Nov 16th, 1:59 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1.700
Open1.700
Bid1.690
Ask2.020
Day's Range1.585 - 1.735
52 Week Range1.585 - 5.478
Volume806,631
Market Cap95.98M
PE Ratio (TTM)-0.9558
EPS (TTM)-1.8
Dividend & YieldN/A (N/A)
1 Month Average Volume1,059,419

Chart

About Voyager Therapeutics, Inc. - Common Stock (VYGR)

Voyager Therapeutics is a biotechnology company focused on developing innovative gene therapies for neurological diseases. The company utilizes its proprietary adeno-associated viral (AAV) platform to create targeted treatments aimed at addressing disorders such as Parkinson's disease, Huntington's disease, and other neurodegenerative conditions. By leveraging advancements in gene delivery techniques, Voyager Therapeutics aims to provide long-lasting solutions that potentially improve the quality of life for patients suffering from these debilitating illnesses. Their commitment to scientific research and clinical development centers around delivering transformative therapies to address significant unmet medical needs in neurology. Read More

News & Press Releases

Voyager Therapeutics Eyes Tau Antibody Data and Alzheimer’s Gene Therapy Dosingmarketbeat.com
Voyager Therapeutics (NASDAQ:VYGR) expects a readout from its tau antibody study in the current quarter and plans to begin dosing patients in its Alzheimer’s gene therapy program in the coming months, CEO Al Sandrock said during a fireside chat. The two programs are part of what Sandrock described
Via MarketBeat · November 16, 2026
Which stocks are moving after the closing bell on Friday?chartmill.com
Via Chartmill · June 5, 2026
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · September 30, 2025
Voyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: Analystbenzinga.com
Voyager's Alzheimer's programs show longer CNS exposure and potential gene therapy advances, with analysts maintaining a Buy rating and $30 price target.
Via Benzinga · September 15, 2025
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 5 Analystsbenzinga.com
Via Benzinga · December 2, 2024
Voyager Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)benzinga.com
Via Benzinga · November 14, 2024
Earnings Scheduled For November 12, 2024benzinga.com
Via Benzinga · November 12, 2024
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · May 9, 2025
7 Analysts Assess Voyager Therapeutics: What You Need To Knowbenzinga.com
Via Benzinga · April 8, 2025
Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Dave, Inc. (NASDAQ: DAVE), Red Cat Holdings, Inc. (NASDAQ: RCAT), Perpetua Resources Corp. (NASDAQ:PPTA), and Voyager Therapeutics, Inc. (NASDAQ:VYGR). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · March 20, 2025
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analystsbenzinga.com
Via Benzinga · March 12, 2025
Preview: Voyager Therapeutics's Earningsbenzinga.com
Via Benzinga · November 11, 2024
In-Depth Examination Of 4 Analyst Recommendations For Voyager Therapeuticsbenzinga.com
Via Benzinga · October 16, 2024
What Analysts Are Saying About Voyager Therapeutics Stockbenzinga.com
Via Benzinga · July 31, 2024
Earnings Scheduled For March 11, 2025benzinga.com
Via Benzinga · March 11, 2025
VOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ:VYGR) on behalf of Voyager stockholders. Our investigation concerns whether Voyager has violated the federal securities laws and/or engaged in other unlawful business practices.
By Bragar Eagel & Squire · Via GlobeNewswire · February 24, 2025
Is VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) suited for growth investing?chartmill.com
Should you consider VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) for growth investing?
Via Chartmill · April 17, 2024
VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. (“Voyager” or “the Company”) (NASDAQ: VYGR) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · February 20, 2025
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · October 22, 2024
Get “Picky” With Stocks For September Profitstalkmarkets.com
Via Talk Markets · September 9, 2024
3 High-Growth Stocks Poised To Double By Next Yeartalkmarkets.com
The article outlines three high-growth stocks that could double by 2025, using specific screening criteria: strong buy ratings from multiple analysts, significant revenue and earnings growth, and substantial recent earnings surprises.
Via Talk Markets · August 28, 2024
7 Biotech Stocks to Buy for Their Game-Changing Potentialinvestorplace.com
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.
Via InvestorPlace · August 8, 2024
VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q2 2024investorplace.com
VYGR stock results show that Voyager Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024
VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q1 2024investorplace.com
VYGR stock results show that Voyager Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 13, 2024
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolioinvestorplace.com
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.
Via InvestorPlace · March 27, 2024